בעמוד זה תמצאו את המחקרים והסקירות המדעיות הכי עדכניות בנושא הקנאביס.
הקישורים בעמוד זה מחולקים לחלק של סקירות מדעיות וחלק של מחקרים קליניים.
סקירה מדעית זו דרך מעולה להתרשם מהממצאים החדשים שמתגלים במחקרים השונים.
סקירות מדעיות בתחום הקנאביס
להלן עשרת הסקירות המדעיות הכי עדכניות לשנת 2020
- מאת Erhan YararThe endocannabinoid system (ECS) is a neuromodulator system with a crucial role in CNS and the reaction to endogenous and exogenous compounds and inflammation. Cannabidiol (CBD) is a basic part of the ECS which is the overwhelming causative and/or protective factor of major depressive disease (MDD). CBD interacts with brain-derived neurotropic factor (BDNF) that responds […]
- Cannabinoids-based Medicine Pharmacology, Drug Interactions, and Perioperative Management of Surgical Patientsמאת Samer NarouzeNo abstract
- Scoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United Statesמאת Thomas M ClarkIntroduction:Cannabis smoke contains carcinogens similar to tobacco, in addition to compounds with antitumor activity. Cannabis use reduces the risk of obesity and cannabinoids inhibit chronic inflammation, known causes of cancer. The net effect of Cannabis use on cancer risk is not known. Objective: To examine the association between Cannabis use and cancer risk in the […]
- מאת Mia C HazleIntroduction: This article proposes a workplace cannabis policy paradigm that encompasses rapidly changing laws and regulations, legally defensible drug testing policies, and the needs of particular workplaces. Numerous states have now decriminalized medical or recreational use of cannabis, although U.S. federal law still defines cannabis as a Schedule I substance with no currently accepted medical […]
- מאת Daniel J CorsiIntroduction: Cannabis is commonly used for its medicinal and therapeutic benefits and is also widely used as a recreational drug. Cannabis use has been increasing in Canada, including among Canadian women of reproductive age. Post-legalization, further increases in cannabis use are expected due to increased availability and lowered perceptions of harm. Although cannabinoids are well […]
- Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Quarterly Progress Report: May 2021מאת Marian S. McDonaghThis is the third quarterly progress report for an ongoing living systematic review on cannabis and other plant-based treatments for chronic pain. The first progress report was published in January 2021 and the second in March 2021. The draft systematic review was available for public comment from May 19 through June 15, 2021, on the […]
- Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Quarterly Progress Report/Addendum: September 2021מאת Marian S. McDonaghThis is the fourth quarterly progress report for an ongoing living systematic review on Cannabis and other Plant-based Treatments for Chronic Pain. The systematic review, available at https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment/living-review, synthesizes evidence on the benefits and harms of plant-based compounds (PBCs), such as cannabinoids and kratom, used to treat chronic pain, addressing concerns about severe adverse effects, […]
- Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Quarterly Progress Report/Surveillance Report 1: September 2021מאת Marian S. McDonaghThis is the fourth quarterly progress report for an ongoing living systematic review on Cannabis and other Plant-based Treatments for Chronic Pain. The systematic review, available at https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment/living-review, synthesizes evidence on the benefits and harms of plant-based compounds (PBCs), such as cannabinoids and kratom, used to treat chronic pain, addressing concerns about severe adverse effects, […]
- Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 2: Literature Update Period: August 2021 through October 2021מאת Marian S. McDonaghThis is the second surveillance report for a living systematic review on cannabis and other plant-based treatments for chronic pain.
- Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 3: Literature Update Period: November 2021 through Mid-January 2022מאת Roger ChouThis is the third surveillance report for a living systematic review on cannabis and other plant-based treatments for chronic pain.
מחקרים קליניים, מטה אנליזות ומחקרים מבוקרים בנושא קנאביס
עשרת המחקרים הכי עדכניים לשנת 2020 בנושא קנאביס. מדובר במחקרים מהסוג של מחקרים קליניים, מטה אנליזות ומחקרים מבוקרים
- מאת Robert S StephensSome adult cannabis users report negative consequences of use but do not seek treatment. Nonjudgmental, brief interventions incorporating motivational interviewing techniques may be able to reach users who otherwise would not seek treatment and increase their motivation to change use. Previous studies have shown brief interventions with this population are efficacious in reducing use, but […]
- Impact of a computerized intervention for high distress intolerance on cannabis use outcomes: A randomized controlled trialמאת Richard J MacateeCONCLUSION: The DTI's impact on all outcomes was largely comparable to the control condition, though it may have utility as an adjunctive intervention.
- Combined prevention for substance use, depression, and anxiety in adolescence: a cluster-randomised controlled trial of a digital online interventionמאת Maree TeessonBACKGROUND: Substance use, depression, and anxiety in adolescence are major public health problems requiring new scalable prevention strategies. We aimed to assess the effectiveness of a combined online universal (ie, delivered to all pupils) school-based preventive intervention targeting substance use, depression, and anxiety in adolescence.
- מאת Randi Melissa SchusterCONCLUSIONS: On average, 4 weeks of incentivized (i.e., paid) cannabis abstinence among non-treatment seeking youth was associated with increased frequency and amount of alcohol use in week 1 that was sustained over 4 weeks and resolved with resumption of cannabis use. However, there was notable variability in individual-level response, with 60% increasing in alcohol use […]
- Computer- vs. nurse practitioner-delivered brief intervention for adolescent marijuana, alcohol, and sex risk behaviors in school-based health centersמאת Jan GryczynskiCONCLUSIONS: CBI and NBI did not yield different risk behavior outcomes in this randomized trial. Supplementary quasi-experimental comparisons suggested potential superiority over assessment-only. Both NBI and CBI could be useful in SBHCs.
- Predictors of substance use in a clinical sample of youth seeking treatment for Trauma-related mental health problemsמאת Zachary W AdamsChild maltreatment and traumatic events are well established risk factors for adolescent substance use problems, but little is known about the unique contributions of etiological factors on trauma-exposed youths' pre-treatment substance use in clinical settings. This study examined associations between substance use and risk and protective factors measured across multiple ecological levels among a unique […]
- Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trialמאת Thomas R ArkellCONCLUSIONS AND RELEVANCE: In a crossover clinical trial that assessed driving performance during on-road driving tests, the SDLP following vaporized THC-dominant and THC/CBD-equivalent cannabis compared with placebo was significantly greater at 40 to 100 minutes but not 240 to 300 minutes after vaporization; there were no significant differences between CBD-dominant cannabis and placebo. However, the […]
- Genetic counselling for the prevention of mental health consequences of cannabis use: A randomized controlled trial-within-cohortמאת Alyson ZwickerCONCLUSION: This study represents the first translational application of a gene-environment interaction to improve mental health and test an intervention with potential public health benefits. This study is registered with clinicaltrials.gov (NCT03601026).
- Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not womenמאת Brian J ShermanCONCLUSION: Findings support existing evidence that early cannabis use onset is associated with worse outcomes and add new knowledge on the differential associations between age of onset, latency to cannabis dependence, and treatment outcomes for men and women.
- Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trialמאת Aaron J RubertoCONCLUSION: In this clinical trial, haloperidol was superior to ondansetron for the acute treatment of cannabis-associated hyperemesis. The efficacy of haloperidol over ondansetron provides insight into the pathophysiology of this now common diagnosis in many EDs.